Luye submitted an NDA to FDA for Rykindo risperidone extended-release microspheres (LY03004) to treat schizophrenia and bipolar disorder. Luye Pharma Group Ltd. (HKSE:2186) hopes to launch the injectable formulation of the generic risperidone in the U.S. and China by next year.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,